Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in newly diagnosed disease or in patients with ear...

Full description

Bibliographic Details
Published in:	Hemato
Main Authors:	Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Subjects:	multiple myeloma immunotherapy antibodies monoclonal bispecific immunoconjugates
Online Access:	https://www.mdpi.com/2673-6357/2/1/7

Similar Items

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1
by: Grant Klug, et al.
Published: (2023-04-01)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
by: Shih-Feng Cho, et al.
Published: (2022-10-01)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021-01-01)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
by: Chloe O'Neill, et al.
Published: (2023-08-01)

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?
by: Andrea Zanello, et al.
Published: (2022-08-01)

Bispecific antibody targets and therapies in multiple myeloma
by: Matthew Rees, et al.
Published: (2024-10-01)

Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
by: Moran Wang, et al.
Published: (2024-06-01)

Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01)

Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01)

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
by: Charalampos Theocharopoulos, et al.
Published: (2021-09-01)

Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
by: Slava Stamova, et al.
Published: (2012-07-01)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
by: Razwana Khanam, et al.
Published: (2023-05-01)

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
by: Ilaria Sorgiovanni, et al.
Published: (2025-01-01)

Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells
by: Liping Ma, et al.
Published: (2021-05-01)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
by: Jiangxue Hou, et al.
Published: (2023-08-01)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
by: Waqqas Tai, et al.
Published: (2022-03-01)

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
by: Ricardo D. Parrondo, et al.
Published: (2024-04-01)

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01)

Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
by: Gianluca Perego, et al.
Published: (2021-12-01)

Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
by: Xin Wang, et al.
Published: (2024-02-01)

The physiological limits of bispecific monoclonal antibody tissue targeting specificity
by: Armin Sepp, et al.
Published: (2025-12-01)

The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
by: Daniele Derudas, et al.
Published: (2024-08-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis
by: Maryam Noori, et al.
Published: (2023-09-01)

Advances in Emerging Therapies for Multiple Myeloma
by: QIAN Chenjing, et al.
Published: (2023-03-01)

CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?
by: Paula Rodriguez-Otero, et al.
Published: (2024-05-01)

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)

Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus
by: Zuning Ren, et al.
Published: (2024-12-01)

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
by: Valeria Ferla, et al.
Published: (2024-07-01)

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment
by: Minchuan Zhang, et al.
Published: (2024-11-01)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
by: Gianfranco Lapietra, et al.
Published: (2022-08-01)

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
by: Kevin E. Ramos, et al.
Published: (2024-07-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
by: Irene Cattaneo, et al.
Published: (2024-02-01)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
by: Jing Wei, et al.
Published: (2022-10-01)

Producing and prospects for the use of bispecific antibodies for the treatment of cancer
by: S. E. Sedykh, et al.
Published: (2019-01-01)

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
by: Serena Rocchi, et al.
Published: (2024-05-01)

Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
by: Federico Caroni, et al.
Published: (2025-01-01)